A5011868198- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Nutrition and Health in Aging
- Glioma Diagnosis and Treatment
- Cancer survivorship and care
- Cancer Treatment and Pharmacology
- Cancer Research and Treatments
- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Immunotherapy and Immune Responses
- Oral health in cancer treatment
- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
- CAR-T cell therapy research
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Treatment and Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Lymphoma Diagnosis and Treatment
Kantonsspital Winterthur
2016-2025
Swiss Group For Clinical Cancer Research
2000-2024
The University of Texas MD Anderson Cancer Center
2004-2023
Indiana University – Purdue University Indianapolis
2004-2023
Princess Margaret Cancer Centre
2004-2023
Winterthur Museum Garden and Library
2008-2019
University Hospital of Basel
2000-2016
Kantonsspital St. Gallen
2005-2013
Stiftung Tumorforschung Kopf-Hals
2013
Kantonsspital Graubünden
2009-2012
To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated chemotherapy.
Purpose: A multicenter, phase II trial investigated the efficacy and toxicity of neoadjuvant docetaxel-cisplatin in locally advanced non–small-cell lung cancer (NSCLC) examined prognostic factors for patients not benefiting from surgery. Patients Methods: Ninety with previously untreated, potentially operable stage IIIA (mediastinoscopically pN2) NSCLC received three cycles docetaxel 85 mg/m 2 day 1 plus cisplatin 40 days 2, subsequent surgical resection. Results: Administered...
For patients with resectable stage IIIA(N2) non-small-cell lung cancer, neoadjuvant chemotherapy cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EFS) rate of 48% the SAKK 16/00 trial is an accepted standard care. We investigated additional benefit perioperative treatment durvalumab.Neoadjuvant consisted three cycles 100 mg/m2 85 once every 3 weeks two doses durvalumab 750 mg 2 weeks. Durvalumab was continued for 1 year after surgery. The primary end...
Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects promoting immune responses. BI1361849 (CV9202) is an active immunotherapeutic comprising protamine-formulated, sequence-optimized mRNA encoding six non-small cell lung (NSCLC)-associated antigens (NY-ESO-1, MAGE-C1, MAGE-C2, survivin, 5T4, MUC-1), intended to induce targeted responses.We describe a phase Ib clinical trial evaluating treatment with combined radiation in 26...
To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated chemotherapy.
The aim was to investigate the efficacy of neoadjuvant docetaxel–cisplatin and identify prognostic factors for outcome in locally advanced stage IIIA (pN2 by mediastinoscopy) non-small-cell lung cancer (NSCLC) patients. In all, 75 patients (from 90 enrolled) underwent tumour resection after three 3-week cycles docetaxel 85 mg m−2 (day 1) plus cisplatin 40 or 50 (days 1 2). Therapy well tolerated (overall grade 3 toxicity occurred 48% patients; no 4 nonhaematological reported), with observed...
BACKGROUND A population‐based analysis of patients with glioma diagnosed between 1980 and 1994 in the Canton Zurich Switzerland confirmed overall poor prognosis glioblastoma. To explore changes outcome, registry data were reevaluated for 2005 2009. METHODS Patients glioblastoma who 2009 identified by Zug Cancer Registry. The prognostic significance epidemiological clinical data, isocitrate dehydrogenase 1 (IDH1) R132H mutation status, O6 methylguanine DNA methyltransferase ( MGMT ) promoter...
BackgroundThe vascular endothelial growth factor antibody bevacizumab (Avastin®), received approval for the treatment of recurrent glioblastoma in many countries including USA and Switzerland, but not European Union, 2009. Here, we explored hypothesis that improved outcome with on a population level.Patients methodsThe prognostic significance epidemiological, molecular genetic, clinical data patients diagnosed from 2010 to 2014 Canton Zurich, was retrospectively analyzed using log-rank test...
Abstract Background The MUC1 protein is a highly glycosylated mucin normally found at the apical surface of mucin‐secreting epithelial cells in many types tissues. expressed, but heavily underglycosylated, different human tumors. TG4010 viral suspension recombinant vaccinia vector (MVA) containing DNA sequences coding for antigen and interleukin‐2 (IL‐2). This product was developed use as vaccine cancer patients whose tumors express antigen. objective present study to determine safety define...
This multicenter phase IB/II trial investigated cetuximab added to preoperative chemoradiotherapy for esophageal cancer.Patients with resectable, locally advanced cancer received two 3-week cycles of induction chemoimmunotherapy (cisplatin 75 mg/m(2) day 1, docetaxel 250 days 8,15 [400 loading dose]) followed by chemoimmunoradiation therapy (CIRT) and surgery. CIRT consisted 45 Gy radiotherapy (RT) plus concurrent cisplatin 25 weekly 5 weeks in cohort 1. If fewer than three seven patients...